Clinical assessment of mocravimod as a victim of drug-drug interactions via CYP3A4 metabolism and transporters
{{output}}
Mocravimod, a novel immunomodulator targeting sphingosine-1-phosphate receptor (S1PR), is being developed as a maintenance treatment for patients with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation. Preclinical data suggested t... ...
